Your browser doesn't support javascript.
loading
Galectin-9 is a target for the treatment of cancer: A patent review.
Rodrigues, Cássia Ferreira; Santos, Francisco Alves; Amorim, Leonardo Andrade Abreu; da Silva, André Luis Coelho; Marques, Lana Grasiela Alves; Rocha, Bruno Anderson Matias.
Afiliação
  • Rodrigues CF; RENORBIO, Federal University of Ceara, Fortaleza, Brazil.
  • Santos FA; Department of Biochemistry and Molecular Biology, Federal University of Ceara, Fortaleza, Brazil.
  • Amorim LAA; Department of Biochemistry and Molecular Biology, Federal University of Ceara, Fortaleza, Brazil.
  • da Silva ALC; Department of Biochemistry and Molecular Biology, Federal University of Ceara, Fortaleza, Brazil; Post Graduate Program in Biotechnology of Natural Resources, Federal University of Ceara, Fortaleza, Brazil.
  • Marques LGA; Post Graduate Program in Biotechnology of Natural Resources, Federal University of Ceara, Fortaleza, Brazil.
  • Rocha BAM; RENORBIO, Federal University of Ceara, Fortaleza, Brazil; Department of Biochemistry and Molecular Biology, Federal University of Ceara, Fortaleza, Brazil; Post Graduate Program in Biotechnology of Natural Resources, Federal University of Ceara, Fortaleza, Brazil. Electronic address: bruno.rocha@ufc
Int J Biol Macromol ; 254(Pt 1): 127768, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38287577
ABSTRACT
Galectins, which correspond to a group of proteins capable of recognizing and reversibly binding to ß-galactoside carbohydrates, have been the subject of innovation and development of technological products. Galectins play biological roles, such as cell proliferation and apoptosis, and some studies showed differences in the concentrations of galectins dispersed in serum of patients with cancer. For this reason, different studies have evaluated the biotechnological potential of these proteins as biomarkers for the prognosis and/or diagnosis of physiological disorders. Thus, this review discusses recent technological advancements in targeting galectins for the treatment of cancer and using galectins for cancer prognosis and diagnosis. Data mining was performed using the search descriptors "Galectin 9* and cancer*" and the ESPACENET and Cortellis Drug Discovery Intelligence (CDDI) databases. PRISMA guidelines were followed as a basis for literature review which aimed to conduct a systematic study of galectin-9 patents related to cancer prognosis, diagnosis and treatment. Results showed the importance of galectin-9 protein patents in furthering biomedical advancements in the global fight against cancer.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Galectinas / Neoplasias Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Int J Biol Macromol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Galectinas / Neoplasias Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Int J Biol Macromol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda